Ironwood Pharmaceuticals Inc
ironwoodpharma.comIronwood Pharmaceuticals (NASDAQ: IRWD) is a biotechnology company that develops and commercializes therapies for gastrointestinal and rare diseases. Revenue comes primarily from LINZESS (linaclotide), its commercial product and the first FDA-approved guanylate cyclase type C agonist, marketed in the U.S. for irritable bowel syndrome with constipation in adults and pediatric patients 7 years and older, chronic idiopathic constipation in adults, and functional constipation in pediatric patients ages 6 to 17. Ironwood supports commercialization through strategic partnerships with pharmaceutical companies in international markets, where linaclotide is sold as LINZESS in Mexico, Japan, and China, and as CONSTELLA in Canada and certain European countries.
Products & Services
LINZESS (linaclotide), a guanylate cyclase type C agonist approved in the U.S. for IBS-C in adults and pediatric patients 7 and older, CIC in adults, and FC in pediatric patients ages 6 to 17. CONSTELLA (linaclotide) marketed in Canada and certain European countries.
Revenue Model
Product revenue and partnership arrangements tied to linaclotide, sold commercially as LINZESS in the U.S. and internationally through strategic pharmaceutical partners under the LINZESS and CONSTELLA trademarks.
Customers & Markets
Adult and pediatric patients with gastrointestinal conditions including irritable bowel syndrome with constipation, chronic idiopathic constipation, and functional constipation. Markets include the U.S., Mexico, Japan, China, Canada, and select European countries.
Geographic Exposure
Primary commercial market is the United States. International presence through partners in Mexico, Japan, China, Canada, and certain European countries.
Financial Snapshot
Loading...
